RxDoctor Payments Data

Jill Breaux

Primary Care · Jennings, LANPI 1598019978

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 41.8% of the total.

$2,583in general payments, 2019–2025

Across 161 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$274
  • GSK$150
  • AstraZeneca$116
  • Ardelyx, Inc.$116
  • Alkermes, Inc.$90
  • plus $758 from 16 others

What the payments were for

  • Food & beverage$2,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,583 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$76,675
MounjaroTirzepatide56$70,453
JardianceEmpagliflozin39$36,710
FarxigaDapagliflozin Propanediol33$32,684
TrulicityDulaglutide16$22,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,610
RexultiBrexpiprazole13$18,769
LinzessLinaclotide24$18,100
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,656
Emgality PenGalcanezumab-Gnlm11$6,933
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,462
SymbicortBudesonide/Formoterol Fumarate11$3,304
Albuterol Sulfate HfaAlbuterol Sulfate62$2,493
SynthroidLevothyroxine Sodium11$1,389
Scopolamine18$1,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$274$92,98772 claims
Novo NordiskOzempic$69$76,67560 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$116$45,64459 claims
GSKTrelegy Ellipta$150$20,61026 claims
AbbVieLinzess, Synthroid$1,079$19,48935 claims
Otsuka America Pharmaceutical, Inc.Rexulti$28$18,76913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 primary care providers in Louisiana.

Other primary care in Jennings

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →